• Vaccine Name: rVSV-Gstem-RSV-F
• Target Pathogen: Human Respiratory Syncytial Virus
• Target Disease: Respiratory tract disease
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: F protein (Johnson et al., 2013)
• Preparation: Recombinant vesicular stomatitis virus (rVSV) replicon in which the attachment and fusion domains of the VSV glycoprotein (G) have been deleted (rVSV-Gstem)(Johnson et al., 2013)
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: Mice were immunized on day 0. In studies that included a boost, mice were boosted at week 4(Johnson et al., 2013)
• Challenge Protocol: RSV challenge virus was administered by the nasal route 4 weeks after the last immunization dose(Johnson et al., 2013)
• Efficacy: (Johnson et al., 2013) A single high dose of the Gstem-RSV-F replicon was effective against challenge with both RSV A and B subgroup viruses. Finally, addition of an RSV glycoprotein (G)-expressing Gstem vector significantly improved the incomplete protection achieved with a single low dose of Gstem-RSV-F vector alone